2019
Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination
Wu Q, Wang X, Pham K, Luna A, Studzinski GP, Liu C. Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination. The Journal Of Steroid Biochemistry And Molecular Biology 2019, 197: 105524. PMID: 31704246, PMCID: PMC7015782, DOI: 10.1016/j.jsbmb.2019.105524.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaVitamin DOral multi-kinase inhibitorTreatment of HCCAutophagy markers Beclin1Vitamin D insufficiencyCarnosic acidAdvanced hepatocellular carcinomaPromising therapeutic optionVitamin D analogsMulti-kinase inhibitorCell linesElevated protein levelsAnti-oxidant propertiesHCC cell linesHuman neoplastic cellsD insufficiencyGlobal cancer mortalityHepatocellular carcinoma cellsSystemic treatmentTherapeutic optionsCancer mortalityHCC cell deathPreclinical studiesLiver cancerTargeting the site encoded by SERPINA1*E342K for treating alpha‐1 antitrypsin deficiency‐associated liver diseases
Zhang X, Pham K, Li D, Schutte RJ, Brantly M, Liu C, Ostrov DA. Targeting the site encoded by SERPINA1*E342K for treating alpha‐1 antitrypsin deficiency‐associated liver diseases. FEBS Letters 2019, 593: 1849-1862. PMID: 31116417, DOI: 10.1002/1873-3468.13452.Peer-Reviewed Original Research
2017
A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma
Wu Q, Pi L, Le Trinh T, Zuo C, Xia M, Jiao Y, Hou Z, Jo S, Puszyk W, Pham K, Nelson DR, Robertson K, Ostrov D, Rameshwar P, Xia CQ, Liu C. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. Molecular Therapy 2017, 25: 2299-2308. PMID: 28865999, PMCID: PMC5628867, DOI: 10.1016/j.ymthe.2017.08.005.Peer-Reviewed Original ResearchConceptsC57/B6 miceHepatocellular carcinomaGlypican-3B6 miceIntravenous infusionImmune responseTumor-specific cytotoxic T lymphocyte responsesCytotoxic T lymphocyte responsesBALB/c miceTumor necrosis factor alphaFirst preclinical evidenceLocal immune responseT lymphocyte responsesLimited treatment optionsDurable tumor regressionNecrosis factor alphaAnti-HCC effectsCultured HCC cellsCTL responsesLymphocyte responsesPreclinical evidenceAntibody therapyMost HCC tissuesHigh morbidityTreatment options